Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL15914113 | 0.93 | RIPK1 (0.43) | LMNARIPK1TRPA1HIF1A | |
| SCHEMBL19381479 | 0.81 | LMNA (0.45) | LMNARIPK1TRPA1TAAR1ADRA2A | |
| SCHEMBL8235740 | 0.81 | LMNA (0.45) | LMNARIPK1TRPA1TAAR1ADRA2A | |
| SCHEMBL27968373 | 0.79 | AOC3 (0.48) | LMNARIPK1SLC6A3SLC6A4KCNH2 | |
| SCHEMBL68538 | 0.78 | RIPK1 (0.45) | LMNARIPK1TRPA1SLC6A3SLC6A4 | |
| SCHEMBL22766210 | 0.78 | RIPK1 (0.45) | LMNARIPK1TRPA1SLC6A3SLC6A4 | |
| SCHEMBL1471159 | 0.78 | SLC6A4 (0.45) | LMNARIPK1SLC6A3SLC6A4CACNA1F | |
| SCHEMBL1911099 | 0.78 | SLC6A4 (0.45) | LMNARIPK1SLC6A3SLC6A4CACNA1F | |
| SCHEMBL12574668 | 0.78 | SLC6A4 (0.45) | LMNARIPK1SLC6A3SLC6A4CACNA1F | |
| SCHEMBL3401038 | 0.76 | LMNA (0.41) | LMNATRPA1ADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071208-A1 | Pest Repellent Composition | KAO CORPORATION (JP) | 2022-03-10 | — | — | US | claimed |
| US-20250302014-A1 | WASP PEST MANAGEMENT SYSTEM | TONER DARADH (IE) | 2025-10-02 | — | — | US | disclosed |
| EP-4518647-A1 | WASP PEST MANAGEMENT SYSTEM | Toner, Daradh (IE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023214095-A1 | WASP PEST MANAGEMENT SYSTEM | TONER DARADH (IE) | 2023-11-09 | — | — | WO | disclosed |
| US-20220071208-A1 | Pest Repellent Composition | KAO CORPORATION (JP) | 2022-03-10 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3398585-B1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | HAYASHIBARA CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-20190008747-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3398585-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20150342854-A1 | EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME | Hayashibara Co., Ltd. (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2939657-A1 | SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR | Hayashibara Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20140221269-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-07 | — | — | US | disclosed |
| US-7799752-B2 | Compositions comprising encapsulated material | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2010-09-21 | — | — | US | disclosed |
| US-20060039934-A1 | Compositions comprising encapsulated material | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2006-02-23 | — | — | US | disclosed |
| US-20050176009-A1 | Nucleotide sequences coding orphan receptors for identifying modulators of smell reception; enhancing odor detection; perfumes | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-08-11 | — | — | US | disclosed |
| EP-1534216-A1 | COMPOSITIONS COMPRISING ENCAPSULATED MATERIAL | Quest International Services B.V. (NL) | 2005-06-01 | — | — | EP | disclosed |
| EP-1393706-A1 | Fragranced compositions comprising encapsulated material | QUEST INTERNATIONAL B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004016234-A1 | COMPOSITIONS COMPRISING ENCAPSULATED MATERIAL | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2004-02-26 | — | — | WO | disclosed |
| US-6325475-B1 | Devices for presenting airborne materials to the nose | MICROFAB TECHNOLOGIES INC. | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | LMNA 3409/4885RIPK1 150/4885TRPA1 2447/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | LMNA 3509/4885RIPK1 214/4885TRPA1 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.